GDUFA II? Mylan Lawyer Questions User Fee Law’s Future Absent FDA Progress
Executive Summary
Generic drug companies will want to see some tangible improvements from agency, including faster ANDA reviews and more approvals, before starting negotiations to reauthorize the user fee law.
You may also be interested in...
Generic User Fee Renewal Talks Faced 'Buyer's Remorse' From GDUFA I
Industry dismay at slow pace of ANDA approvals and FDA communications in early years of first user fee agreement factored into GDUFA II negotiations.
Generic User Fee Renewal Talks Faced 'Buyer's Remorse' From GDUFA I
Industry dismay at slow pace of ANDA approvals and FDA communications in early years of first user fee agreement factored into GDUFA II negotiations.
FDA Generics Office To Be Managed By Relative Unknown
Director Uhl’s medical leave puts bioequivalence office head John Peters in the limelight.